Removing Applications from some Teams result in 500-error

I'm trying to remove some legacy applications we run from our development team but just lands on a 500-error page, this can be reproduced on some teams but not others.

I can reproduce the problem by trying to remove any of our applications to the "Users" team, this get me to land on the 500-error page.

For the support (specific reproduce procedure): For the team "Tulo Projects" I'm trying to remove the Adeprimo.Dealie.* (for example: Adeprimo.Dealie.Admin) and get the 500-error.

Regars Erik

---

Tacrolimus (also FK-506 or fujimycin, swop names Prograf, Advagraf, Protopic) is an immunosuppressive opiate that is primarily in use accustomed to after allogeneic organ move to subdue the endeavour of the passive's exempt set-up and so lower the gamble of medium rejection. It is also occupied in a local preparation in the treatment of atopic dermatitis (eczema), severe refractory uveitis after bone marrow transplants, exacerbations of slightest change infirmity, and the fleece form vitiligo. It is a 23-membered macrolide lactone discovered in 1984 from the fermentation decoction of a Japanese filth test that contained the bacteria Streptomyces tsukubaensis. It reduces interleukin-2 (IL-2) forming by T-cells. Olden days Tacrolimus was discovered in 1984; it was middle the maiden macrolide immunosuppressants discovered, preceded at near the disclosure of rapamycin (sirolimus) on Rapa Nui (Easter Eyot) in 1975.<>] It is produced by a type of loam bacterium,Streptomyces tsukubaensis.<>] The handle tacrolimus is derived from 'Tsukuba macrolide immunosuppressant'.<>] Tacrolimus was first approved during the Edibles and Narcotize Supplying (FDA) in 1994 in compensation use in liver transplantation; this has been extended to include kidney, affection, uncomfortable bowel, pancreas, lung, trachea, skin, cornea, bone marrow, and limb transplants. Availability The branded type of the dull is owned sooner than Astellas Pharma, and is sold under the marketing names Prograf assumption twice everyday,Advagraf, a sustained launch formulation allowing once day after day dosing, and Protopic (Eczemus in Pakistan before Brookes Pharma), the up to date formulation.<>] Advagraf is at one's fingertips in 0.5, 1, 3 and 5 mg capsules, the not bad is concentrations of 0.1% and 0.03%. A second once-daily formulation of tacrolimus is in Development 3 clinical trials in the U.S. and Europe. This formulation also has a smoother pharmacokinetic list that reduces the peak-to-trough rank in blood levels compared to twice-daily tacrolimus.<>] Statistics from the primary Time 3 litigation in deep-rooted kidney transplant patients showed that this once-daily formulation was non-inferior in efficacy and protection compared to twice-daily tacrolimus.<>] A next Condition 3 litigation in de novo patients is ongoing.<>] Mechanism of vigour Tacrolimus is chemically known as a macrolide. In T-cells, activation of the T-cell receptor normally increases intracellular calcium, which acts via calmodulin to turn on calcineurin. Calcineurin then dephosphorylates the transcription factor NF-AT (nuclear agent of activated T-cells), which moves to the nucleus of the T-cell and increases the labour of genes coding to save IL-2 and tied up cytokines. Tacrolimus prevents the dephosphorylation of NF-AT.<>] In charge, Tacrolimus reduces peptidyl-prolyl isomerase occupation via binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex. This FKBP12-FK506 complex interacts with and inhibits calcineurin therefore inhibiting both T-lymphocytesignal transduction and IL-2 transcription.<>] Although this action is similar to ciclosporin, studies take shown that the occurrence of dangerous repudiation is reduced about tacrolimus exigency execrate above ciclosporin.<>0] Although short-term immunosuppression concerning unyielding and shoot survival is institute to be comparable between the two drugs, tacrolimus results in a more favorable lipid profile, and this may eat urgent long-term implications foreordained the prognostic act upon of denial on graft survival.<>1]

---